Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 3
2015 2
2016 3
2017 6
2018 2
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership.
Bridges S, Fowler S, McLaughlin L, Robichaud M, Ridgway B, Reece D, Song K, Dalrymple L, Sully R, Nason S, Rowland S, MacDonald T, Paine W, Gulliver A, Reiman A. Bridges S, et al. Among authors: mclaughlin l. Res Involv Engagem. 2023 Jul 29;9(1):60. doi: 10.1186/s40900-023-00476-9. Res Involv Engagem. 2023. PMID: 37516883 Free PMC article.
Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson's disease.
Chaudhuri SE, Ben Chaouch Z, Hauber B, Mange B, Zhou M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Caldwell B, Benz HL, Ho M, Saha A, Gwinn K, Sheldon M, Lo AW. Chaudhuri SE, et al. Among authors: mclaughlin l. J Biopharm Stat. 2023 Mar 2:1-20. doi: 10.1080/10543406.2023.2170400. Online ahead of print. J Biopharm Stat. 2023. PMID: 36861942
The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership.
Fowler S, McLaughlin L, Bridges S, Robichaud M, Ridgway B, Reece D, Song K, Dalrymple L, Sully R, Nason S, Rowland S, MacDonald T, Paine W, Reiman A. Fowler S, et al. Among authors: mclaughlin l. Br J Haematol. 2022 Mar;196(5):e52-e54. doi: 10.1111/bjh.17946. Epub 2021 Nov 6. Br J Haematol. 2022. PMID: 34741302 Free PMC article. No abstract available.
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease.
Benz HL, Caldwell B, Ruiz JP, Saha A, Ho M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Mange B, Hauber AB, Gwinn K, Heetderks WJ, Sheldon M. Benz HL, et al. Among authors: mclaughlin l. MDM Policy Pract. 2021 Jul 2;6(1):23814683211021380. doi: 10.1177/23814683211021380. eCollection 2021 Jan-Jun. MDM Policy Pract. 2021. PMID: 34277950 Free PMC article.
Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study.
Hauber B, Mange B, Zhou M, Chaudhuri S, Benz HL, Caldwell B, Ruiz JP, Saha A, Ho M, Christopher S, Bardot D, Sheehan M, Donnelly A, McLaughlin L, Gwinn K, Lo A, Sheldon M. Hauber B, et al. Among authors: mclaughlin l. MDM Policy Pract. 2021 Jan 18;6(1):2381468320978407. doi: 10.1177/2381468320978407. eCollection 2021 Jan-Jun. MDM Policy Pract. 2021. PMID: 33521289 Free PMC article.
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. McLaughlin LP, et al. Blood. 2018 Nov 29;132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub 2018 Sep 27. Blood. 2018. PMID: 30262660 Free PMC article. Clinical Trial.
22 results